Failure of hormone deprivation therapy used to slow prostate cancer in patients leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options. Endostatin, used in combination therapy, may help delay onset of castration-resistant disease.
March is Colorectal Cancer Awareness Month, and UAB kicks it off with an inaugural Colon on the Green event March 3.
A UAB study shows specialized treatment sites contribute to better survival rates for those with acute leukemia. 
Pam Alverson, UAB'S Employee of the Month, maintains a calm, stabilizing presence in a sometimes-overwhelming arena of clinical research.
UAB Comprehensive Cancer Center holds annual ArtBLINK Gala to support high-priority and life-saving research. 
UAB’s innovative Patient Care Connect Program utilizes lay navigation and provides a cost-effective new model for cancer care delivery.
The UAB Comprehensive Cancer Center has received a $16 million NCI renewal grant to advance cancer disparities research and reduce mortality rates among underserved populations.
A key Leukemia & Lymphoma Society grant will provide an opportunity for a UAB researcher to develop a new immunotherapy treatment approach for the leukemia most prevalent in Western countries.
The Nov. 15 Lunch and Learn event will provide patients and employers with information about working during cancer treatment.
Priming the body to respond to immunotherapy with a new class of drugs: epigenetic modifiers.
Page 2 of 10